Investors

Notice of Annual General Meeting & Investor Presentation

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitute announces its audited results for the 12 months ended 31 December 2024

Download To view a full version of the results in  PDF format  click here

 

Highlights

• £1,004k orders received with reportable revenue for the year up 35% to £870k (2023: £644k)
• Sales and marketing investment in Ecommerce, India and the USA starting to show strong returns across all areas of the business reducing dependency on a small number of partners or territories:-

• Ecommerce sales up from £186k to £387k (+108%) with Amazon sales up 156% and a 290% increase in subscriptions
• Launch of products in India with Morepen in December 2024 leading to £171k of revenues, up from marginal revenues in 2023
• Good early sales growth in Asia, albeit from a low base
• First order received from a USA partner, Daily Nouri

• Launch of LeanBiome in MuscleTech, a market leader in sports nutrition
• Clearance of the large stock overhang at Maxum (48mt) and Cambridge Commodities (16mt) which has impacted on reportable revenues in the last few years 
• Fixed operating costs are slightly lower for the year £1,605k (2023: £1,662k). We anticipate fixed costs to reduce in 2025 through reductions in PR, Broker and staff costs
• The Company ended 2024 with a strong balance sheet of £9m (2023: £9.4m), a strong cash position of £739k (2023: £635k), no debt and a growing pipeline of existing customers reordering and new customers looking to launch
  

Post period end

• The recovery in sales in 2023 and sales growth in 2024 has continued into 2025 with order book for Q1 2025 higher than the sales achieved H1 2024. 
• Launch of first product in the USA, a FeelFull prebiotic lemonade containing SlimBiome®, by Daily Nouri
• Launch of products containing SlimBiome® with a NASDAQ listed partner
• First order from a leading weight management brand in the USA looking to launch two products containing SlimBiome online and subsequently in Walmart USA
• New six metric tonne order received from Brenntag in Q2, the Company’s new Australian distributor
• New customers in Asia in 2025 at various stages of product development and launch ensuring continued strong growth in this region
• Repeat order from Morepen in H1 with larger order expected in H2 as the products enter retail. New product development underway to expand product range
• Study published in European Journal of Nutrition looking at glycaemic control and insulin response. Study conducted in partnership with leading US weight management brand
• Successful placing to raise £750,000 in May 2025 to support sales growth in the USA
• Ongoing discussions with a number of major brands to incorporate SweetBiotix and microbiome modulators in their products

 

The Annual Report and Financial Statements, which will be sent to shareholders today, contains a Notice of Annual General Meeting (“AGM”) which will be held at 12pm on 6 August 2025 at the offices of Walbrook PR, 75 King William St, London, EC4N 7BE. 

Investor briefing

Stephen O’Hara and his team will provide a live presentation to investors to discuss the results via the Investor Meet Company platform on Thursday, 3 July 2025 at 2pm BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet OptiBiotix.

To register for the presentation, please use this link: https://www.investormeetcompany.com/optibiotix-health-plc/register-investor

Stephen O’Hara, CEO of OptiBiotix Health plc said: “After restructuring the management team in 2023 and focus on investing in key strategic markets in the USA, India, and ecommerce, 2024 has seen strong sales growth across all areas of these businesses. Sales have continued to grow in 2025 and should accelerate as we see the full year effect of 2024 launches, new partners launching products in the USA and Asia, and ecommerce continuing its growth trajectory with the launch of products on Amazon India. 

“Our investments in sales and marketing are starting to deliver a multi-channel, multi territory revenue stream, reducing reliance on a single partner or territory. We continue to see sales momentum building across all areas with Q1 sales and orders in 2025 higher than H2 2024 and continuing in Q2. This has been helped by a 6mt order from Brenntag in Australia.  We are particularly pleased to have cleared the large stock overhang held in Australia and the UK which has impacted on reportable revenues in the last few years.  

“As the Company reduces its PR, broker, and staff costs and its investment in marketing and R&D, and continues to grow its top line and improves margins, all parts of the business should become profitable and the Group generate positive cashflow.

“This means we enter 2025 with a strong balance sheet (£9m) and cash position (2024: £739k; 2023: £635k) no debt, a strong order book supported by a pipeline of existing customers reordering, new customers looking to launch, and appreciating assets through our shareholdings in PBX and SBTX. 

“On behalf of the Board, I would like to thank our shareholders for their patience and ongoing support, and anticipate continuing on an upward trajectory for the remainder of 2025 and beyond.”

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

 

For further information, please contact:

OptiBiotix Health plc		www.optibiotix.com
Neil Davidson, Chairman	Contact via Walbrook below
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD & Broker)		Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Walbrook PR Ltd		Mob: 07876 741 001
Anna Dunphy

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.